



## Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020

August 6, 2020

*Presentations to be webcast on Cortexyme's website*

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 6, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases, today announced Casey Lynch, the company's chief executive officer, chair, and co-founder, will present at the following two investor conferences in August 2020:

- The Canaccord Genuity 40<sup>th</sup> Annual Growth Conference: Ms. Lynch's presentation will start at 2:00 p.m. EDT / 11:00 a.m. PDT on Wednesday, August 12.
- The JMP Securities CNS Forum: Ms. Lynch will participate in a fireside chat at 1:00 p.m. EDT / 10:00 a.m. on Wednesday, August 19.

Both events will take place virtually, with live webcasts accessible at the [Investor Calendar](#) page under the News & Events heading of the Cortexyme investor site ([ir.cortexyme.com](http://ir.cortexyme.com)). Each webcast will be archived at that location for 30 days.

### About Cortexyme, Inc.

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the [GAIN Trial](#), an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer's patients and tied to neurodegeneration and neuroinflammation in animal models. To learn more about Cortexyme, visit [www.cortexyme.com](http://www.cortexyme.com) or follow [@Cortexyme](#) on Twitter.

### Forward-Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, the translation to humans of pre-clinical data; the pre-clinical results for our product candidates, the timing and success of our clinical trials and related data, the potential of atuzaginstat to treat Alzheimer's disease and cardiovascular disease, our ability to fund planned operating and capital expenditures, the timing of announcements and updates relating to our clinical trials and related data, the timing of and our ability to enroll patients into our clinical trials, and the potential therapeutic benefits, safety and efficacy of our product candidate or library of compounds. Forward-looking statements are based on Cortexyme's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on May 12, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20200806005920/en/>

### Media Contact:

Hal Mackins  
For Cortexyme, Inc.  
[hal@torchcomllc.com](mailto:hal@torchcomllc.com)  
(415) 994-0040

### Investor Contact:

Chris Lowe  
Chief Financial Officer  
Cortexyme, Inc.  
[clowe@cortexyme.com](mailto:clowe@cortexyme.com)

Source: Cortexyme, Inc.